---
title: "Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299784967.md"
description: "Truist Financial analyst Danielle Brill reiterated a Buy rating on Maze Therapeutics with a $64 price target, citing expanding APOL1 inhibitor opportunities in AMKD. Vertex's positive Phase 2 data suggest a broader patient population exceeding 100,000, supporting a multi-billion-dollar market for MAZE's lead asset MZE829. H.C. Wainwright also maintained a Buy rating with a higher $110 price target."
datetime: "2026-09-22T14:35:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299784967.md)
  - [en](https://longbridge.com/en/news/299784967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299784967.md)
generator: "portal-rs"
---

# Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained

Truist Financial analyst Danielle Brill maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $64.00.

Danielle Brill has given his Buy rating due to a combination of factors tied to the expanding APOL1 inhibitor opportunity in AMKD. Vertex’s positive Phase 2 data suggest APOL1 inhibition can benefit a much broader set of AMKD patients beyond FSGS, pointing to an addressable population exceeding 100,000 patients and supporting a multi‑billion‑dollar market in which MAZE can participate.

This enlarged market underpins the view that MAZE’s lead asset, MZE829, can achieve blockbuster‑level sales even if its efficacy and safety profile merely matches that of inaxaplin. Brill also highlights potential differentiation if MZE829 shows a cleaner hepatic safety profile amid transaminase elevation signals seen with Vertex’s drug, while noting that some uncertainty around diabetic AMKD remains but is directionally supportive. The price target is unchanged at $64, reflecting strengthened long‑term fundamentals without altering the valuation framework.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $110.00 price target.

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [MAZE.US](https://longbridge.com/en/quote/MAZE.US.md)
- [TFC.US](https://longbridge.com/en/quote/TFC.US.md)

## Related News & Research

- [Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75](https://longbridge.com/en/news/300722738.md)
- [2 Healthcare Stocks That Just Delivered Great News for Investors](https://longbridge.com/en/news/300206760.md)
- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**